# Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Study · id `cardio:ct-nct01447862` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01447862](<https://clinicaltrials.gov/study/NCT01447862>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01447862

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT01447862. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT01447862, source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01447862, source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01447862, source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)
- Completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01447862, source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)
- Countries: Austria (ClinicalTrials.gov record NCT01447862, source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01447862-2015-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): Brinavess (Vernakalant)
- Intervention (Drug): Corvert (Ibutilide)
- Lead sponsor: Medical University of Vienna
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medical University of Vienna (`cardio:org-medical-university-of-vienna`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department (`cardio:pubmed-28175295`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0565c0281eacd8bb77aa60e0edc80e3e320f487c49dc9de18ccc57836e326ea1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
